US 12,285,430 B2
Methods of treating disorders using CSF1R inhibitors
Daniel L. Flynn, Waltham, MA (US); Bryan D. Smith, Waltham, MA (US); Rodrigo Ruiz Soto, Waltham, MA (US); and Keisuke Kuida, Waltham, MA (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Apr. 28, 2023, as Appl. No. 18/140,942.
Application 18/140,942 is a continuation of application No. 17/358,137, filed on Jun. 25, 2021, granted, now 11,679,110.
Application 17/358,137 is a continuation of application No. 16/725,282, filed on Dec. 23, 2019, granted, now 11,103,507, issued on Aug. 31, 2021.
Claims priority of provisional application 62/933,830, filed on Nov. 11, 2019.
Claims priority of provisional application 62/926,341, filed on Oct. 25, 2019.
Claims priority of provisional application 62/786,105, filed on Dec. 28, 2018.
Prior Publication US 2023/0414614 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/505 (2006.01); A61K 9/00 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/513 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 18 Claims
 
1. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound represented by:

OG Complex Work Unit Chemistry
wherein after 1 month or more of administration, the patient has: (i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or (ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.